Comprehensive Online Oncology Database	REPORT FORMAT Marketed Drug Market Status Table Note: Report links have been disabled for this sample screen.	SUBSCRIBER SEARCH (Requires Login) NEW DRUG MARKETED DRUG COMPANY TARGETS IN ONCOLOGY NEWS AND WEBCAST SUMMARIES COMBINATION TRIALS
1-949-830-0448		info@newmedinc.com

Your search found 4 records. Click on a developer link to see more information.

Developer	Designation	Description	Approved/Filed Indications
Barr Pharmaceuticals Current as of: November 21, 2007	Generic Name: Thalidomide	Thalidomide is an antiangiogenic compound that blocks certain growth factors such asvascular endothelial growth factor (VEGF) and bFGF. Administration Route: PO	• cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) in leprosy
BioAlliance Pharma Affiliate(s): · Par Pharmaceutical Current as of: December 04, 2007	Generic Name: Miconazole Brand Name: Loramyc • Miconazole Lauriad	Loramyc comprises miconazole, an antifungal agent with broad-spectrum activity against various species of Candida, formulated with the Lauriad extended release tablet delivery platform (miconazole Lauriad bioadhesive buccal tablet). Administration Route: PO	• oropharyngeal candidiasis in immunocompromized patients, particularly those with head and neck cancer treated with radiotherapy, and those infected with HIV
GlaxoSmithKline Affiliate(s): · University of Florida Gainsville Current as of: December 02, 2007	Generic Name: Topotecan Brand Name: Hycamtin, Hycaptamine Other Designation: NSC-609699, SK&F-104864	Topotecan, a water-soluble camptothecin analog, is a topoisomerase I inhibitor. Administration Route: intravenous (IV) • PO • intracerebral	• ovarian cancer, metastatic, second or third line-IV • small cell lung cancer (sclc), refractory, second line treatment-IV • small cell lung cancer (sclc), relapsed, when retreatment with the first line regimen is not considered appropriate, IV • cervical cancer, Stage IVb recurrent or persistent not amenable to curative treatment with surgery and/or radiation therapy, in combination with cisplatin-IV • small cell lung cancer (sclc), relapsed-PO
PharmaMar Affiliate(s): · Ortho Biotech Products · University of Illinois · Swedish Orphan International · Genesis Pharma Current as of: December 02, 2007	Generic Name: Trabectedin Brand Name: Yondelis Other Designation: Ecteinascidin 743, ET-743, NSC 648766	Trabectedin, a novel marine compound derived from the tunicate Ecteinascidia turbinata, is a cytotoxic alkaloid and a DNA minor groove, guanine-specific interacting agent that also targets topo I, inducing topo I-mediated protein-linked DNA breaks. Administration Route: intravenous (IV), intermittent • intravenous (IV), continuous	• soft tissue sarcoma, refractory to standard treatments

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM